TGFB2

Across TCGA pan-cancer cohorts, TGFB2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TGFB2 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TGFB2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TGFB2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LSCC, UCEC, and HNSC are the cancer types where TGFB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	All	0.497	0.795	.008	24	view →
UCEC	DFS	Tertile	II,III,IV	0.919	0.388	.007	20	view →
HNSC	OS	Tertile	IV	0.508	0.829	.008	15	view →
PDAC	DFS	Tertile	All	0.300	0.457	.016	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TGFB2–LSCC (DFS)

Open the LSCC breakdown →